Pharmanutra SpA
MIL:PHN

Watchlist Manager
Pharmanutra SpA Logo
Pharmanutra SpA
MIL:PHN
Watchlist
Price: 54 EUR -1.1% Market Closed
Market Cap: 522.7m EUR
Have any thoughts about
Pharmanutra SpA?
Write Note

Net Margin
Pharmanutra SpA

13.6%
Current
17%
Average
3.3%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
13.6%
=
Net Income
21.4m
/
Revenue
157.8m

Net Margin Across Competitors

Country IT
Market Cap 518.8m EUR
Net Margin
14%
Country FR
Market Cap 181.7B EUR
Net Margin
15%
Country UK
Market Cap 114.1B GBP
Net Margin
11%
Country IN
Market Cap 5.5T INR
Net Margin
17%
Country UK
Market Cap 34.9B GBP
Net Margin
11%
Country DE
Market Cap 27.8B EUR
Net Margin
8%
Country US
Market Cap 27B USD
Net Margin
1%
Country JP
Market Cap 3T JPY
Net Margin
5%
Country IN
Market Cap 1.1T INR
Net Margin
-3%
Country IN
Market Cap 903.7B INR
Net Margin
14%
Country US
Market Cap 9.9B USD
Net Margin
12%
No Stocks Found

Pharmanutra SpA
Glance View

Market Cap
518.8m EUR
Industry
Consumer products

Pharmanutra SpA develops nutraceutical products and medical devices. The company is headquartered in Pisa, Pisa. The company went IPO on 2017-07-18. The firm develops nutraceutical products and medical devices. The company focuses on studying and producing formulations that are backed up in scientific research. The company is able to cover all stages of the development of a product, from its design, formulation and registration to its marketing, distribution and training of its commercial representatives. The firm offers Gestalys DHA, a nutritional supplement; Cetilar, a massage coadiuvant, improves and brings relief to joints affected by osteoarthritis; Cetilar patch, a transdermic patch containing a concentrated formulation of cetylated fatty acids (CFA) esters; SiderAL Forte; CardioSiderAL; SiderAL Folico; SiderAL; Bonecal and Novomega, among others.

PHN Intrinsic Value
42.67 EUR
Overvaluation 21%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
13.6%
=
Net Income
21.4m
/
Revenue
157.8m
What is the Net Margin of Pharmanutra SpA?

Based on Pharmanutra SpA's most recent financial statements, the company has Net Margin of 13.6%.